Tags

Type your tag names separated by a space and hit enter

[Prevalence of anti-hepatitis A in patients with chronic liver disease].
Gastroenterol Hepatol. 1998 Aug-Sep; 21(7):324-6.GH

Abstract

The recent availability of an effective vaccine for preventing hepatitis A has led to the performance of a prevalence study of antibodies versus the hepatitis A virus (HAV) in our patients with chronic liver disease by hepatitis B and C, as a step prior to vaccination. The sera of 425 patients with a mean age of 40 years was studied, with the global antibodies versus HAV being determined (Abbott). The prevalence was to 75.2% varying from 20% at 19 years to 93% in those over the age of 40. The prevalence was not related to sex, previous parenteral history, or drug addiction or infection by hepatitis B or C. Due to previous cost-benefit studies and the high prevalence found, the determination of anti-HAV in patients with chronic viral liver diseases prior to vaccination against HAV is recommended.

Authors+Show Affiliations

Servicio de Digestivo, Hospital General Universitario, Valencia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

9808894

Citation

Diago, M, et al. "[Prevalence of Anti-hepatitis a in Patients With Chronic Liver Disease]." Gastroenterologia Y Hepatologia, vol. 21, no. 7, 1998, pp. 324-6.
Diago M, Luján M, García V, et al. [Prevalence of anti-hepatitis A in patients with chronic liver disease]. Gastroenterol Hepatol. 1998;21(7):324-6.
Diago, M., Luján, M., García, V., Cors, R., Carbonell, P., Tuset, C., & Gimeno, J. (1998). [Prevalence of anti-hepatitis A in patients with chronic liver disease]. Gastroenterologia Y Hepatologia, 21(7), 324-6.
Diago M, et al. [Prevalence of Anti-hepatitis a in Patients With Chronic Liver Disease]. Gastroenterol Hepatol. 1998 Aug-Sep;21(7):324-6. PubMed PMID: 9808894.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Prevalence of anti-hepatitis A in patients with chronic liver disease]. AU - Diago,M, AU - Luján,M, AU - García,V, AU - Cors,R, AU - Carbonell,P, AU - Tuset,C, AU - Gimeno,J, PY - 1998/11/11/pubmed PY - 1998/11/11/medline PY - 1998/11/11/entrez SP - 324 EP - 6 JF - Gastroenterologia y hepatologia JO - Gastroenterol Hepatol VL - 21 IS - 7 N2 - The recent availability of an effective vaccine for preventing hepatitis A has led to the performance of a prevalence study of antibodies versus the hepatitis A virus (HAV) in our patients with chronic liver disease by hepatitis B and C, as a step prior to vaccination. The sera of 425 patients with a mean age of 40 years was studied, with the global antibodies versus HAV being determined (Abbott). The prevalence was to 75.2% varying from 20% at 19 years to 93% in those over the age of 40. The prevalence was not related to sex, previous parenteral history, or drug addiction or infection by hepatitis B or C. Due to previous cost-benefit studies and the high prevalence found, the determination of anti-HAV in patients with chronic viral liver diseases prior to vaccination against HAV is recommended. SN - 0210-5705 UR - https://www.unboundmedicine.com/medline/citation/9808894/[Prevalence_of_anti_hepatitis_A_in_patients_with_chronic_liver_disease]_ L2 - http://www.diseaseinfosearch.org/result/4280 DB - PRIME DP - Unbound Medicine ER -